Filament Health Corp.

FLHLF

CA31685W1068

Advanced Medical Equipment & Technology

Market Closed - OTC Markets Other stock markets 14:47:13 25/06/2024 BST			5-day change	1st Jan Change
0.0335 ^USD	+0.15%		+11.67%	-38.08%

06-12	Filament Health Corp. announced that it has received CAD 1 million in funding from Negev Capital	CI
06-03	Filament Health Announces Authorization of Phase 2 Clinical Trial for PEX010 in the Treatment of Methamphetamine Use Disorder	CI

Filament Health Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 14, 2024 at 08:21 pm

Filament Health Corp. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was CAD 0.297932 million.

Net loss was CAD 0.907177 million compared to CAD 1.25 million a year ago.

Latest news about Filament Health Corp.

Filament Health Corp. announced that it has received CAD 1 million in funding from Negev Capital	06-11	CI
Filament Health Announces Authorization of Phase 2 Clinical Trial for PEX010 in the Treatment of Methamphetamine Use Disorder	06-03	CI
Filament Health Corp. announced that it expects to receive CAD 1 million in funding from Negev Capital and another investor	06-02	CI
Filament Health Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Filament Health Corp. Announces Change to Board of Directors	05-03	CI
Filament Health Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	04-03	CI
Filament Health Corp. Announces Appointment of Michael Messinger to Its Board of Directors and Chair of the Audit Committee	03-28	CI
Filament Health Corp. Announces Chief Financial Officer Changes	03-28	CI
Filament Health Corp. Announces Shipments of Botanical Psilocybin to Four Countries for Clinical Investigation	03-19	CI
Filament Health Corp. Completes the First Export of Botanical Psilocybin to Israel	02-15	CI
Filament Health Announces FDA Opening of Investigational New Drug Application for Substance Use Disorders	01-31	CI
Filament Health Completes the First Export of Biological Psilocybin to Australia	01-17	CI
Filament Health Announces Change to Board of Directors	01-03	CI
Filament Health Corp. (OTCPK:FLHL.F) cancelled the acquisition of Jupiter Acquisition Corporation from a group of shareholders in a reverse merger transaction.	12-17	CI
Filament Health Corp. announced that it has received CAD 0.9 million in funding from Negev Capital	12-05	CI
Filament Health Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Filament Health Announces Health Canada Authorization for Phase 2 Clinical Trial Studying Botanical Psilocybin for Opioid Use Disorder	09/10/23	CI
Filament Health Corp. announced that it expects to receive CAD 2 million in funding from Negev Capital	28/09/23	CI
Filament Health Corp. Enters Licensing Agreement with Reset Pharmaceuticals Inc	30/08/23	CI
Filament Health Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	13/08/23	CI
Filament Health Corp. Announces FDA Approval of Two Clinical Trials Studying Its Biological Psychedelic Drug Candidate PEX010	08/08/23	CI
Filament Health Corp. announced that it has received CAD 2.5 million in funding from Negev Capital	23/07/23	CI
Jupiter Acquisition Corporation entered into a definitive agreement to acquire Filament Health Corp. (OTCPK:FLHL.F) from shareholders for approximately $150 million.	18/07/23	CI
Filament Health Corp. announced that it expects to receive CAD 2 million in funding from Negev Capital	18/07/23	CI
Filament Health Corp. to Supply Psilocybin for Two Clinical Trials	07/07/23	CI

Filament Health Corp. is a Canada-based clinical-stage natural psychedelic drug development company. The Companyâs platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. The Companyâs first three botanical drug candidates are standardized, purified extracts of psilocybe cubensis fruiting bodies include: PEX010 Psilocybin - oral delivery (1mg and 25mg), PEX020 Psilocin - oral delivery (dose withheld), and PEX030 Psilocin - sublingual delivery (dose withheld). The Company's preclinical stage drug candidates include AEX010 Ayahuasca - oral delivery (dose withheld), and AEX020 Monoamine Oxidase Inhibitor - oral delivery (dose withheld). The Companyâs internal drug discovery and development program is carried out by its wholly owned subsidiary, Psilo Scientific Ltd., and is focused on developing standardized pharmaceutical-grade drug candidates from botanical psychedelic biomass.

Sector

Advanced Medical Equipment & Technology

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
FILAMENT HEALTH CORP.	-38.08%	8.49M
THERMO FISHER SCIENTIFIC	+4.85%	212B
DANAHER CORPORATION	+9.86%	188B
INTUITIVE SURGICAL, INC.	+31.11%	157B
BOSTON SCIENTIFIC CORPORATION	+34.08%	114B
SIEMENS HEALTHINEERS AG	+1.90%	64.01B
EDWARDS LIFESCIENCES CORPORATION	+19.45%	54.88B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+1.63%	48.83B
AGILENT TECHNOLOGIES, INC.	-3.12%	39.3B
GE HEALTHCARE TECHNOLOGIES INC.	+1.93%	35.97B

Other Advanced Medical Equipment & Technology